{
    "clinical_study": {
        "@rank": "168304", 
        "arm_group": [
            {
                "arm_group_label": "Treatment AB", 
                "arm_group_type": "Experimental", 
                "description": "S->S+C"
            }, 
            {
                "arm_group_label": "Treatment C", 
                "arm_group_type": "Experimental", 
                "description": "C"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the pharmacokinetics profile and drug-drug\n      interaction between amlodipine, olmesartan and rosuvastatin in healthy adult volunteers."
        }, 
        "brief_title": "Pharmacokinetics and Drug Interaction Study Between Amlodipine,Olmesartan and Rosuvastatin in Healthy Adult Volunteers", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male subjects aged 19 - 55 years\n\n          -  A body mass index in the range 19 - 27 kg/m2\n\n          -  Willingness to participate during the entire study period\n\n          -  Written informed consent after being fully informed about the study procedures\n\n        Exclusion Criteria:\n\n          -  Any past medical history of hepatic, renal, gastrointestinal, respiratory, endocrine,\n             psychiatric, neurologic, haemato-oncologic or  cardiovascular disease\n\n          -  History of clinically significant drug hypersensitivity\n\n          -  Use of medication within 7 days before the first dose\n\n          -  Heavy drinker (>140 g/week)\n\n          -  Whole blood donation during 60 days before the study\n\n          -  Judged not eligible for study participation by investigator"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02089399", 
            "org_study_id": "DW_DWJ1351001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment AB", 
                "description": "Treatment AB", 
                "intervention_name": "Sevikar(amlodipne/olmesartan)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment AB", 
                    "Treatment C"
                ], 
                "description": "Treatment AB/Treatment C", 
                "intervention_name": "crestor(Rosuvastatin)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Olmesartan", 
                "Olmesartan medoxomil", 
                "Rosuvastatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Samsung medical center"
            }, 
            "investigator": {
                "last_name": "Jaewook Ko, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open Label, Randomized, 2-Sequence, Multiple-Dose, Cross-Over Study to Investigate the Drug-Drug Interaction of Sevikar and Crestor in Healthy Adult Volunteers", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "AUCtau", 
                "safety_issue": "No", 
                "time_frame": "Multiple blood sample will be collected for 24 hours after last dosing in each of the treatment"
            }, 
            {
                "measure": "Css,max", 
                "safety_issue": "No", 
                "time_frame": "Multiple blood sample will be collected for 24 hours after last dosing in each of the treatment"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02089399"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Tss,max", 
                "safety_issue": "No", 
                "time_frame": "Multiple blood sample will be collected for 24 hours after last dosing in each of the treatment"
            }, 
            {
                "measure": "Css,min", 
                "safety_issue": "No", 
                "time_frame": "Multiple blood sample will be collected for 24 hours after last dosing in each of the treatment"
            }
        ], 
        "source": "Daewoong Pharmaceutical Co. LTD.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Daewoong Pharmaceutical Co. LTD.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}